Evidence map›Paper›PMID 28451756›Full record

ArticleVirchows Archiv : an international journal of pathology2017

Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift.

Alessandra Fabbri, Mara Cossa, Angelica Sonzogni, Paolo Bidoli, Stefania Canova, Diego Cortinovis, Maria Ida Abbate, Fiorella Calabrese, Nazarena Nannini, Francesca Lunardi and 11 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.Virchows Archiv : an international journal of pathology · 2026
    Review
  2. Article
  3. Diagnostic issues in neuroendocrine neoplasms of the lung.Pathologie (Heidelberg, Germany) · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Morphologic and molecular classification of lung neuroendocrine neoplasms.Virchows Archiv : an international journal of pathology · 2021
    Review
  9. Article
  10. Article
  11. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019
    Article
  12. Article
  13. Article
  14. Pulmonary neuroendocrine carcinomas-evidence for a spectrum of differentiation.Virchows Archiv : an international journal of pathology · 2018
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 2 countries.

Alessandra FabbriDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Mara CossaDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Angelica SonzogniDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Paolo BidoliDivision of Medical Oncology, San Gerardo Hospital, Monza, Italy.
Stefania CanovaDivision of Medical Oncology, San Gerardo Hospital, Monza, Italy.
Diego CortinovisDivision of Medical Oncology, San Gerardo Hospital, Monza, Italy.
Maria Ida AbbateDivision of Medical Oncology, San Gerardo Hospital, Monza, Italy.
Fiorella CalabreseDepartment of Cardiothoracic and Vascular Sciences, Pathological Anatomy Section, University of Padua Medical School, Padua, Italy.
Nazarena NanniniDepartment of Cardiothoracic and Vascular Sciences, Pathological Anatomy Section, University of Padua Medical School, Padua, Italy.
Francesca LunardiDepartment of Cardiothoracic and Vascular Sciences, Pathological Anatomy Section, University of Padua Medical School, Padua, Italy.
Giulio RossiDivision of Anatomic Pathology, Regional Hospital "Umberto Parini", Aosta, Italy.
Stefano La RosaInstitute of Pathology, University Hospital-CHUV, Lausanne, Switzerland.
Carlo CapellaDepartment of Surgical and Morphological Sciences, University of Insubria, Varese, Italy.
Elena TamboriniDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Federica PerroneDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Adele BusicoDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Iolanda CaponeDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Barbara ValeriDepartment of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Ugo PastorinoDivision of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Adriana AlbiniLaboratory of Vascular Biology and Angiogenesis, Science & Technology Park, IRCCS MultiMedica Group, Milan, Italy.
Giuseppe PelosiDepartment of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy. giuseppe.pelosi@unimi.it.ORCID http://orcid.org/0000-0003-4725-4692
Fondazione IRCCS Istituto Nazionale dei Tumori · ITAzienda Ospedaliera San Gerardo · ITUniversity of Padua · ITMultiMedica · ITOspedali Riuniti Umberto I · ITUniversity Hospital of Lausanne · CHUniversity of Insubria · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report an uncommon association of intimately admixed atypical carcinoid (AC) and large cell neuroendocrine (NE) carcinoma (LCNEC) of the thymus, occurring in two 20- and 39-year-old Caucasian males. Both tumors were treated by maximal thymectomy. The younger patient presented with a synchronous lesion and died of disease after 9 months, while the other patient was associated with a recurrent ectopic adrenocorticotropic hormone Cushing's syndrome and is alive with disease at the 2-year follow-up. MEN1 syndrome was excluded in either case. Immunohistochemically, disarrayed cytoplasmic and nuclear ß-catenin expression was seen alongside an intra-tumor Ki-67 antigen labeling index (LI) ranging from 2 to 80% in the younger patient's tumor and from 3 to 45% in the other. Both exhibited upregulated cyclin D1 and retinoblastoma, while vimentin was overexpressed in the recurrent LCNEC only. Next-generation sequencing revealed CTNNB1, TP53, and JAK3 mutations in the synchronous tumor and CTNNB1 mutation alone in the metachronous tumor (the latter with the same mutation as the first tumor of 17 years prior). None of the 23 T-NET controls exhibited this hallmarking triple alteration (p = 0.003). These findings suggested that LCNEC components developed from pre-existing CTNNB1-mutated AC upon loss-of-function TP53 and gain-of-function JAK3 mutations in one case and an epithelial-mesenchymal transition upon vimentin overexpression in the other case. Both tumors maintained intact cyclin D1-retinoblastoma machinery. Our report challenges the concept of secondary LCNEC as an entity that develops from pre-existing AC as a result of tumor progression, suggesting a paradigm shift to the current pathogenesis of NET.

Indexed as

Adultbeta CateninCarcinoma, NeuroendocrineDisease ProgressionHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryKi-67 AntigenMaleMutationThymus NeoplasmsYoung Adultbeta CateninCTNNB1 protein, humanKi-67 AntigenAtypical carcinoidImmunohistochemistryLarge cell neuroendocrine carcinomaNext-generation sequencingß-cateninThymus

Identifiers

PMID28451756
OpenAlexW2609929059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.